Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 4Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Lung Neoplasms 24Thymoma 2Sarcoma 2Mesothelioma, Malignant 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Adenocarcinoma of Lung 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Melanoma 1

Interventions

pembrolizumab 70Nivolumab 24Docetaxel 17Cisplatin 15Paclitaxel 13Carboplatin 12Gemcitabine 8Cetuximab 8Ipilimumab 7durvalumab 6avelumab 6atezolizumab 6Radiotherapy 6Cyclophosphamide 6spartalizumab 5Trastuzumab 5Taxes 5Pemetrexed 5Erlotinib Hydrochloride 5tremelimumab 4cemiplimab 4Specimen Handling 4Leucovorin 4Interleukin-2 4Fluorouracil 4Capecitabine 4Biopsy 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4utomilumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × Celecoxib × Thoracic × Clear all
NCT00058006 2012-06-11

Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer

Northwestern University

Phase 2 Completed
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡